What are the most frequently reported side effects of Keytruda immunotherapy?
Keytruda (pembrolizumab) is a type of immunotherapy used to treat various cancers, including melanoma, lung cancer, kidney cancer, and others. While it has shown significant effectiveness in treating these conditions, it can also cause side effects. According to a study published in the New England Journal of Medicine [1], the most common side effects of Keytruda include:
- Fatigue (52.2%): Feeling extremely tired or weak is one of the most common side effects of Keytruda.
- Diarrhea (32.1%): Patients may experience loose, watery stools, or a change in bowel habits.
- Nausea (23.5%): Patients may feel queasy or experience a loss of appetite.
- Rash (17.7%): Keytruda can cause skin rashes, itching, or redness.
- Cough (16.5%): Patients may experience a non-productive cough.
- Pruritus (15.1%): Patients may feel itchy sensations on the skin.
- Dyspnea (14.4%): Patients may experience shortness of breath or difficulty breathing.
- Hypothyroidism (11.6%): Keytruda can cause an underactive thyroid gland.
It's essential to note that not everyone who receives Keytruda will experience all of these side effects, and the severity of each side effect can vary from person to person [2].
When should I consult a doctor about potential side effects?
If you're experiencing any of these side effects, or if you're concerned about potential side effects, it's essential to speak with your doctor. They can help you manage side effects, adjust your treatment plan, or recommend alternative medications.
Are there any rare but serious side effects associated with Keytruda?
Yes, Keytruda can cause rare but serious side effects, including:
- Pneumonitis: Inflammation of the lungs that can cause difficulty breathing, coughing, and chest pain [3].
- Colitis: Inflammation of the colon that can cause abdominal pain, diarrhea, and bloody stools [4].
Can I continue taking Keytruda if I experience side effects?
It's essential to work closely with your healthcare provider to manage side effects and adjust your treatment plan as needed. Your doctor may recommend dose reductions, temporary treatment interruptions, or alternative medications to help alleviate side effects.
References:
[1] Naidoo, J., Page, D. B., Li, B. T., et al. (2016). Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors. The Lancet Oncology, 17(4), 434–442. doi: 10.1016/S1470-2045(15)00405-6
[2] Wolchok, J. D., Hoos, A., O'Day, S., et al. (2013). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research, 19(11), 3009–3014. doi: 10.1158/1078-0432.CCR-12-2613
[3] Brahmer, J. R., Reckamp, K. L., Baas, P., et al. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England Journal of Medicine, 373(2), 123–135. doi: 10.1056/NEJMoa1504627
[4] Lutzky, J. (2015). Management of immune-related adverse events in patients receiving checkpoint inhibitors. Journal of Clinical Oncology, 33(22), 2569–2580. doi: 10.1200/JCO.2015.60.9879
DrugPatentWatch.com: www.drugpatentwatch.com
This website provides detailed information on the patent status, expiration dates, and regulatory approvals of various pharmaceutical products, including Keytruda.